好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Hyperbaric Oxygen Treatment Improves Non-Arteritic Central Retinal Artery Occlusion: an Observational Retrospective Study
Cerebrovascular Disease and Interventional Neurology
P5 - Poster Session 5 (8:00 AM-9:00 AM)
13-008
We aim to investigate the benefit of hyperbaric oxygen therapy (HBOT) in patients with central retinal artery occlusion (CRAO) compared to conservative management.
CRAO is a form of acute ischemic stroke that causes severe visual loss, which is a relatively rare emergency but devastating condition. There is currently no guideline-endorsed treatment. Data on HBOT for CRAO is minimal. 

We conducted a retrospective single-center study that recruited patients with diagnosed non-arteritic CRAO from January 2019 - May 2024. HBOT was offered to patients who presented within 24 hours from symptom onset. Eight patients underwent a full course of HBOT (twice a day for five days). Twelve patients received partial HBOT (1 to 7 treatments); HBOT discontinued per patients' request due to either anxiety or no noted visual improvement. Twenty-seven patients did not undergo HBOT due to being outside treatment window or patients declined HBOT. The primary outcome was visual improvement at the time of discharge. Paired T-test was used to compare the change in LogMAR best-corrected visual acuity (BCVA) in patients before and after HBOT. 
Patients who completed the full HBOT course showed significant improvement using LogMAR BCVA from 2.7±0.3 pre-HBOT to 2.2±0.4 post-HBOT (p=0.003). No significant changes were observed in the partial HBOT group (2.4±0.6 to 2.2±0.5, p=0.52) or the non-HBOT group (2.3±0.5 pre and post, p=0.36). Only one patient experienced a seizure during HBOT, with no other complications reported. Demographics and vascular risk factors showed no significant differences among the three groups.
HBOT improves visual outcomes in CRAO patients who complete full therapy, but partial HBOT does not provide similar benefits. Our results suggests that HBOT is safe and should be offered to CRAO patients who present to the hospital within 24 hours of symptom onset. A large-scale prospective study is needed to validate our retrospective results.
Authors/Disclosures
Naser Haj Aissa, MBBS
PRESENTER 		Dr. Haj Aissa has nothing to disclose.
Majesta Hovingh, MS Prof. Hovingh has received personal compensation for serving as an employee of Corewell Health Hospital.
Laurel Packard (Corewell Health) Laurel Packard has nothing to disclose.
Asad Ahrar, MD (Corwell Health) Dr. Ahrar has nothing to disclose.
Malgorzata Miller, MD (Corewell Health) The institution of Dr. Miller has received research support from NIH StrokeNet VERIFY trial.
Nadeem I. Khan, MD (Spectrum Health) Dr. Khan has nothing to disclose.
Nabil Wees, MD (Augusta University) Dr. Wees has nothing to disclose.
Jiangyong Min, MD (Corewell Health West) Dr. Min has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic . Dr. Min has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for CredentialMed, LLC. The institution of Dr. Min has received research support from Corerwell Health Foundation .